Targeting ATR in patients with cancer
NYL Ngoi, PG Pilié, DJ McGrail… - Nature Reviews …, 2024 - nature.com
Pharmacological inhibition of the ataxia telangiectasia and Rad3-related protein
serine/threonine kinase (ATR; also known as FRAP-related protein (FRP1)) has emerged as …
serine/threonine kinase (ATR; also known as FRAP-related protein (FRP1)) has emerged as …
Biology and Development of DNA-Targeted Drugs, Focusing on Synthetic Lethality, DNA Repair, and Epigenetic Modifications for Cancer: A Review
K Watanabe, N Seki - International Journal of Molecular Sciences, 2024 - mdpi.com
DNA-targeted drugs constitute a specialized category of pharmaceuticals developed for
cancer treatment, directly influencing various cellular processes involving DNA. These drugs …
cancer treatment, directly influencing various cellular processes involving DNA. These drugs …
Telomere-related DNA damage response pathways in cancer therapy: prospective targets
L Gu, M Liu, Y Zhang, H Zhou, Y Wang… - Frontiers in …, 2024 - frontiersin.org
Maintaining the structural integrity of genomic chromosomal DNA is an essential role of
cellular life and requires two important biological mechanisms: the DNA damage response …
cellular life and requires two important biological mechanisms: the DNA damage response …
The Novel ATR Inhibitor Tuvusertib (M1774) Induces Replication Protein Overexpression and Broad Synergy with DNA-targeted Anticancer Drugs
Abstract Ataxia Telangiectasia and Rad3-related (ATR) checkpoint kinase inhibitors are in
clinical trials. Here we explored the molecular pharmacology and therapeutic combination …
clinical trials. Here we explored the molecular pharmacology and therapeutic combination …
Microenvironment shapes small-cell lung cancer neuroendocrine states and presents therapeutic opportunities
Small-cell lung cancer (SCLC) is the most fatal form of lung cancer. Intratumoral
heterogeneity, marked by neuroendocrine (NE) and non-neuroendocrine (non-NE) cell …
heterogeneity, marked by neuroendocrine (NE) and non-neuroendocrine (non-NE) cell …
The Novel ATR Inhibitor M1774 Induces Replication Protein Overexpression and Broad Synergy with DNA-targeted Anticancer Drugs
Ataxia telangiectasia and Rad3-related (ATR) checkpoint kinase inhibitors are in clinical
trials. Here we explored the molecular pharmacology and therapeutic combination …
trials. Here we explored the molecular pharmacology and therapeutic combination …
Big Decisions on Small Cell Lung Cancer: A Focus on Clinical Care Updates and Patient Perspectives
X Wang, AC Chiang - … Society of Clinical Oncology Educational Book, 2024 - ascopubs.org
Small cell lung cancer (SCLC) is an uncommon, aggressive high-grade neuroendocrine
carcinoma, associated with tobacco use. It is a highly chemosensitive disease that initially …
carcinoma, associated with tobacco use. It is a highly chemosensitive disease that initially …
[HTML][HTML] SIRPG promotes lung squamous cell carcinoma pathogenesis via M1 macrophages: a multi-omics study integrating data and Mendelian randomization
G Mao, J Li, N Wang, H Yu, S Han, M Xiang… - Frontiers in …, 2024 - ncbi.nlm.nih.gov
Background Squamous cell carcinoma of the lung (LUSC) is a severe and highly lethal
malignant tumor of the respiratory system, and its molecular mechanisms at the molecular …
malignant tumor of the respiratory system, and its molecular mechanisms at the molecular …
Non-linear IV pharmacokinetics of the ATR inhibitor berzosertib (M6620) in mice
JJ Deppas, BF Kiesel, J Guo, RA Parise… - Cancer Chemotherapy …, 2024 - Springer
Background The Ataxia Telangiectasia and Rad3-related (ATR) protein complex is an apical
initiator of DNA damage response pathways. Several ATR inhibitors (ATRi) are in clinical …
initiator of DNA damage response pathways. Several ATR inhibitors (ATRi) are in clinical …
ANP32E drives vulnerability to ATR inhibitors by inducing R-loops-dependent Transcription Replication Conflicts in Triple Negative Breast Cancer
S Lago, V Poli, L Fol, M Botteon, A Fasciani, A Turdo… - bioRxiv, 2024 - biorxiv.org
Oncogene-induced replicative stress (RS) plays a central role in tumor progression, leading
to genomic instability by eliciting transcription replication conflicts (TRCs), which represent …
to genomic instability by eliciting transcription replication conflicts (TRCs), which represent …